PRESENT POSITION

  • Physician | 2020 - present | SWGA Nephrology Clinic, P.C. | Private Practice of Nephrology
  • Adjunct Associate Professor | 2020 - present | UT-Health San Antonio | San Antonio, TX. Department of Medicine, Division of Nephrology

PAST ACADEMIC RANK AND POSITION

  • Tenured Associate Professor | 2017 - 2020 | UT-Health San Antonio | San Antonio, TX. Department of Medicine, Division of Nephrology
  • Tenured Associate Professor | 2015 - 2017 | Penn State University College of Medicine | Hershey, PA. Department of Medicine, Division of Nephrology
  • Associate Professor | 2013 - 2015 | Penn State University College of Medicine | Hershey, PA. Department of Medicine, Division of Nephrology
  • Assistant Professor | 2009 - 2013 | Penn State University College of Medicine | Hershey, PA. Department of Medicine, Division of Nephrology
  • Assistant Professor | 2005 - 2009 | University of Virginia | Charlottesville, VA. Department of Medicine, Division of Nephrology
  • Instructor in Medicine | 2004 - 2005 | University of Virginia | Charlottesville, VA. Department of Medicine, Division of Nephrology

EDUCATION

  • Medical School: Cairo University School of Medicine, EGYPT | M.D., 1997
  • M.Sc. of Clinical Research: University of Virginia | M.D., 2008
  • Internship: Penn State Hershey | Medical Center | Hershey, PA 2013-2015
  • Residency: Penn State Hershey | Medical Center | Hershey, PA 2015-2017
  • Fellowship: UT-Health San Antonio | San Antonio, TX 2017-2019

BOARD CERTIFICATION

  • 2018 | American Board of Internal Medicine
  • 2019 | American Board of Internal Medicine | Subspecialty Nephrology

MEDICAL LICENSURE

  • Georgia 87102
  • Texas S0424
  • Pennsylvania MD472149

HONORS/AWARDS

  • 2018 | Karen L. Campbell, PhD, ASN Award
  • 2015 | Inspired Award Faculty Assembly", Penn State College of Medicine
  • 2014 | On stage recognition "the Inspired Together Faculty Assembly", Penn State College of Medicine
  • 2013 | Investigator (innovator) to Watch Award, Penn State College of Medicine
  • 2013 | Department of Medicine Junior Faculty Research Award, Penn State College of Medicine
  • 2009 | Northwestern University Feinberg School of Medicine Cardiovascular Junior Faculty Investigator Award, First Place Award
  • 2008 | American Society of Nephrology Travel Award
  • 2006 | Fellow of the American society of Nephrology
  • 2005 | Northwestern University Feinberg School of Medicine Cardiovascular Junior Faculty Investigator Award, First Place Award
  • 2003 | New Investigator Award, 57th Annual Fall Conference and Scientific Sessions of the Council for High Blood Pressure, American Heart Association
  • 2002 | New Investigator Award, 56th Annual Fall Conference and Scientific Sessions of the Council for High Blood Pressure, American Heart Association

EDUCATION-JOURNALS

  • 2016-2018 | American Physiological Society Award Committee
  • 2010-2016 | American Journal of Nephrology Editorial Board

PROFESSIONAL MEMBERSHIP AND SOCIETIES

  • 2004-present | American Society of Nephrology
  • 2011-present | American Physiological Society
  • 2013-present | American College of Physicians
  • 2007-present | National Kidney Foundation

PRESENTATIONS AT NATIONAL MEETINGS

  • 2002 | 56th Annual Fall Conference and Scientific Sessions of the Council for High Blood Pressure | Renal Nitric Oxide Production is Decreased in Diabetic Rats and Improved by AT1 Receptor Blockade.
  • 2003 | The Endocrine Society’s Annual Meeting | Increased Renal Production of Angiotensin II and Thromboxane B2 in Conscious diabetic Rats.
  • 2003 | The Endocrine Society’s Annual Meeting | Increased Renal Production of Tumor Necrosis Factor alpha in Conscious Diabetes Rats.
  • 2003 | 57th Annual Fall Conference and Scientific Sessions of the Council for High Blood Pressure | Aldosterone Production in Post-Myocardial Ischemia.
  • 2003 | 57th Annual Fall Conference and Scientific Sessions of the Council for High Blood Pressure | De Novo Renal Aldosterone Production and Regulation by Salt Intake.
  • 2003 | 57th Annual Fall Conference and Scientific Sessions of the Council for High Blood Pressure | Diabetes Stimulates Local Renal Aldosterone Production via Angiotensin II AT1 Receptor.
  • 2004 | American Society of Nephrology 37th Annual Meeting | Reno-Protective Effect of Adenosine 2A Receptor (A2AR) Agonists in Diabetic Nephropathy.
  • 2005 | American Society of Nephrology 38th Annual Meeting | Selective Sphingosine 1-Phosphate Type-1 (S1P1) Receptor Activation Reduces Ischemia-Reperfusion Injury in Mouse Kidney.
  • 2006 | American Society of Nephrology 39th Annual Meeting | Activation of podocyte adenosine 2A receptors (A2ARs) preserves structural and functional integrity of podocytes following puromycin aminonucleoside (PAN)-induced injury.
  • 2007 | American Society of Nephrology 40th Annual Meeting | Prevention of Diabetic Nephropathy (DN) Using Sphingosine 1-Phosphate (S1P) Activation.
  • 2008 | American Society of Nephrology 41st Annual Meeting | Neutrophil Compartmentation in Kidney and Lung Following Acute Kidney Injury.
  • 2009 | American Society of Nephrology 42nd Annual Meeting | Lymphocyte-Independent Effect of Sphingosine 1-Phosphate 1 Receptor (S1P1R) Activation Attenuates Diabetic Nephropathy (DN).
  • 2010 | American Society of Nephrology 43rd Annual Meeting | Monocyte/Macrophage Chemokine Receptor CCR2 Mediates Diabetic Renal Injury.
  • 2011 | American Society of Nephrology 44th Annual Meeting | Conditional Ablation of Macrophages Ameliorates Diabetic Nephropathy.
  • 2012 | American Society of Nephrology 45th Annual Meeting | Arginase Inhibition Mediates Renal Tissue Protection in Diabetic Nephropathy via a Nitric Oxide Synthase 3-Dependent Mechanism.
  • 2012 | American Society of Nephrology 45th Annual Meeting | A Small Bioactive Peptide of Pigment Epithelium-Derived Factor reduces Diabetic Renal Injury.
  • 2014 | American Society of Nephrology 47th Annual Meeting | Macrophages-TNF-α Mediates Diabetic Renal Injury.
  • 2015 | American Society of Nephrology 48th Annual Meeting | Arginase Inhibition: A New Treatment for Preventing Progression of Established Diabetic Nephropathy.
  • 2016 | American Society of Nephrology 49th Annual Meeting | CCR2 Expression in Podocytes Mediates Diabetic Renal Injury.
  • 2019 | American Society of Nephrology 52nd Annual Meeting | L-homoarginine Supplementation Prevents Diabetic Kidney Damage.
  • 2020 | American Society of Nephrology 53rd Annual Meeting | Enhancing Kidney DDAH-1 Expression by Adenovirus Delivery Reduces ADMA and Ameliorates Diabetic Nephropathy.

PRESENTATIONS AT INTERNATIONAL MEETINGS

  • 2006 | 8th International Symposium of Adenosine and Adenine Nucleotides. Ferrara, Italy | Adenosine 2A Receptor (A2AR) Agonists Protect Kidneys in Diabetic Nephropathy.
  • 2009 | Gordon Research conference Meeting, Lucca (Barga) Italy | Adenosine 2A (A2A) Agonists Attenuate Inflammation and Restores Endothelial Function in Diabetic Nephropathy (DN) by Regulating Renal Nitric Oxide (NO) Production.
  • 2010 | 10th World Congress on Inflammation. Paris, France | MONOCYTE/MACROPHAGE CHEMOKINE RECEPTOR CCR2 MEDIATES DIABETIC RENAL INJURY.
  • 2012 | Gordon Research conference Meeting, Lucca (Barga) Italy | Arginase Inhibition Mediates Renal Tissue Protection in Diabetic Nephropathy via a Nitric Oxide Synthase 3-Dependent Mechanism.

RESEARCH GRANTS

Title: Role of Arginase in Diabetic Nephropathy     
Principal Investigator: Alaa Awad 
Agency: National Institutes of Health  
Type: R01 DK 094930
Period: 07/15/2012 to 06/30/2019 
Summary: This study focuses on the role of arginases in diabetic nephropathy. 

Title: Role of Arginase in Diabetic Nephropathy “Supplement”
Principal Investigator: Alaa Awad 
Agency: National Institutes of Health 
Type: R01 DK 094930 S1 [PAR14-006] - Seeding Collaborations for Translational Research to Discover and Develop New Therapies for Diseases and Conditions within NIDDK's Mission (Revisions) (R01)
Period: 09/15/2014 to 06/30/2019 
Summary: The specific objective of this proposal is to build upon the PI’s recently funded R01 (DK 094930; Role of Arginase in Diabetic Nephropathy) to undertake several parallel efforts to develop preliminary chemical hits as potential pharmacotherapeutics for diabetic nephropathy. This is a study section reviewed proposal.

Title:  Bayer Protocol 16244
Principal Investigator:  Alaa Awad
Agency:  Bayer HealthCare
Summary: A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone, in addition to standard of care, on the progression of kidney disease in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease.

Title:  Bayer Protocol 17530
Principal Investigator:  Alaa Awad
Agency:  Bayer HealthCare
Summary: A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone on the reduction of cardiovascular morbidity and mortality in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease in addition to standard of care.

Title:  Role of a Small Bioactive peptide of Pigment Epithelium-Derived Factor in Diabetic Nephropathy
Principal Investigator:  Alaa Awad
Agency:  Novo Nordisk Diabetes and Obesity Science Biologics Science
Period:  02/01/2013 to 01/31/2016
Summary:   The major roles of this project are to define the role of a small bioactive peptide of pigment epithelium-derived factor in diabetic nephropathy. 

Title: Chemokines and Immune Cells in Diabetic Nephropathy
Principal Investigator: Alaa Awad                                             
Agency: PA Tobacco Settlement Fund (TSF).
Period: 04/10/2012 to 06/30/2014
Summary: The major goals of this project are to define the role of podocytes and endothelial cells expressing CCR2 in diabetic nephropathy. 

Title: Podocyte Microenvironment in Diabetic Nephropathy     
Principal Investigator: Alaa Awad 
Agency: National Institutes of Health  
Type: K99/R00 DK077444
Period: 09/01/2007 to 08/31/2013 
Summary: This study focuses on the role of macrophage and macrophage/podocyte interaction in diabetic nephropathy. 

Title: ACQUISITION OF A CRYO-ELECTRON MICROSCOPE
Principal Investigator: Susan Hafenstein
Co-Investigator: Alaa Awad                                             
Agency: National Institutes of Health  
Type: 1S10OD011986-01A1
Period: 04/01/2012 to 03/31/2013
Summary: This is instrumental grant for Penn State College of Medicine.

Title: Evaluation of Anti-inflammatory Agents to Attribute Nephropathy Parameters in a Mouse Model of Diabetic Nephropathy
Principal Investigator: W. Brian Reeves
Co-Investigator: Alaa Awad                                             
Agency: Johnson & Johnson Pharmaceutical Research & Development, LLC
Period: 09/14/2011 to 09/13/2012
Summary: The major goals of this project are to define the role of inflammatory cytokines in diabetic nephropathy. 

Title: Reno-Protective Effect of Adenosine 2A Receptor Agonist in Diabetic Nephropathy
Principal Investigator: Alaa Awad 
Agency: National Kidney Foundation 
Type: Grant In-Aid
Period: July 1, 2004 to June 30, 2007
Summary: This study focuses on the role of A2A receptor activation in diabetic nephropathy.

Title: Adenosine in Renal Injury                                      
Principal Investigator: Mark D Okusa                                
Co-Investigator: Alaa S Awad                                             
Agency: National Institutes of Health  
Type:  R01 DK56223   
Period: July 1, 2005 – June 30, 2009
Summary: This study focuses on the effect of A2A-agonist in diabetic nephropathy

Title: Adenosine 2A Agonists in Renal Protection from Type 1 Diabetes                                           
Principal Investigator: Mark D Okusa                                
Co-Investigator: Alaa S Awad                                             
Agency: Juvenile Diabetes Research Foundation 
Period: July 1, 2005 – June 30, 2008
Summary: The study focuses on the role of bone marrow derived A2ARs in mediating tissue protection, in diabetic nephropathy. 

PATENT DISCLOSURES

U.S. Patent #: 7,396,825 (Issue Date: 07/08/2008): Agonists of A2A Adenosine Receptors to Treat or Prevent Diabetic Nephropathy

U.S. Patent #: 13/469,731 (Issue Date: 05/13/2011): Treatment of Renal Injury

BIBLIOGRAPHY

  1. Wetzel MD, Stanley K, Maity S, Madesh M, Bopassa JC, Awad AS. Homoarginine ameliorates diabetic nephropathy independent of nitric oxide synthase-3. Physiol Rep. 2021 Mar;9(5):e14766. PMID: 33713581. PMCID: PMC7955794. 
  2. Defronzo R, Reeves WB, Awad AS. Pathophysiology of Diabetic Kidney Disease: Effect of SGLT2 Inhibition. Nature Review of Nephrology; Nat Rev Nephrol. 2021 Feb 5. doi: 10.1038/s41581-021-00393-8. Online ahead of print. PMID: 33547417.
  3. Wetzel MD, Stanley K, Wang W, Maity S, Muniswamy M, Reeves WB, Awad AS. Selective Inhibition of Arginase-2 in Endothelial Cells but not Proximal Tubules Reduces Renal Fibrosis. JCI Insight. 2020 Oct 2;5(19):142187. PubMed PMID: 32956070.
  4. Wetzel MD, Gao T, Stanley K, Cooper TK, Morris SM, Awad AS. Enhancing Kidney DDAH-1 Expression by Adenovirus Delivery Reduces ADMA and Ameliorates Diabetic Nephropathy. Am J Physiol Renal Physiol. 2020 Feb 1;318(2):F509-F517. PubMed PMID: 31904280.
  5. Wetzel MD, Gao T, Venkatachalam M, Morris SM, Awad AS. L-homoarginine supplementation prevents diabetic kidney damage. Physiol Rep. 2019 Sep;7 (18), e14235. PMCID: PMC6759505.
  6. Morris SM, You H, Gao T, Vacher J, Cooper TK, Awad AS. “Distinct roles of arginases 1 and 2 in diabetic nephropathy”. Am J Physiol Renal Physiol. 2017 Oct 1;313(4):F899-F905. PMCID: PMC5668588.
  7. You H, Gao T, Raup-Konsavage WM, Cooper TK, Bronson SK, Reeves WB, Awad AS. “Podocyte-Specific CCR2 Expression Mediates Diabetic Renal Injury”. Kidney Int. 2017 Mar;91(3):671-682. PMCID: PMC5313320.
  8. Awad AS, You H, Gao T, Gvritishvili A, Cooper TK, Tombran-Tink J. “Delayed Treatment with a Small Pigment Epithelium Derived Factor (PEDF) Peptide Prevents the Progression of Diabetic Renal Injury”. PLoS One. 2015 Jul 24;10(7):e0133777. PMCID: PMC4514848.
  9. Awad AS, You H, Gao T, Cooper TK, Nedospasov SA, Vacher J, Wilkinson PF, Farrell FX, Reeves WB. “Macrophage-derived TNF-α Mediates Diabetic Renal Injury”. Kidney Int. 2015 Oct;88(4):722-33. PMCID: PMC4589442.
  10. You H, Gao T, Cooper TK, Morris SM, Awad AS. “Arginase Inhibition: A New Treatment for Preventing Progression of Established Diabetic Nephropathy”. Am J Physiol Renal Physiol. 2015 Sep 1;309(5):F447-55. PMCID: PMC4556892. 
  11. Sun YW, El-Bayoumy K, Aliaga C, Awad AS, Gowda K, Amin S, Chen KM. “Tissue Distribution, Excretion and Pharmacokinetics of the Environmental Pollutant Dibenzo[def,p]chrysene in Mice”. Chem Res Toxicol. 2015 Jul 20;28(7):1427-33. PMCID: PMC4863960.
  12. You H, Gao T, Cooper TK, Morris SM, Awad AS. “Diabetic Nephropathy is Resistant to Oral L-Arginine or L-Citrulline Supplementation”. Am J Physiol Renal Physiol. 2014 Dec;307(11):F1292-301. PMCID: PMC4254967. 
  13. You H, Gao T, Cooper TK, Morris SM, Awad AS. “Arginase Inhibition Mediates Renal Tissue Protection in Diabetic Nephropathy via a Nitric Oxide Synthase 3-Dependent Mechanism”. Kidney Int. 2013 Dec;84(6):1189-97. PMCID: PMC3783645.
  14. You H, Gao T, Cooper TK, Reeves WB, Awad AS. “Macrophages directly mediate diabetic renal injury”. Am J Physiol Renal Physiol. 2013 Dec;305(12):F1719-27. PMCID: PMC3882451.
  15. Awad AS, Gao T, Gvritishvili A, You H, Liu Y, Cooper TK, Reeves WB, Tombran-Tink J. “Protective role of small pigment epithelium-derived factor (PEDF) peptide in diabetic renal injury”. Am J Physiol Renal Physiol. 2013 Sep 15;305(6):F891-900. PMCID: PMC3761290.
  16. Abdel-Rahman EM, Alhamad T, Reeves WB, Awad AS. Management of Diabetic Nephropathy in Elderly: Special Considerations. J Nephrol Therapeut 2012, 2:124. PMCID: PMC3760431.
  17. Reeves WB, Rawal BB, Abdel-Rahman EM, Awad AS. Therapeutic Modalities in Diabetic Nephropathy: Future Approaches. Open Journal of Nephrology. 2012 June (2): 5-18. PMCID: PMC3534956.
  18. Abdel-Rahman EM, Saadulla L, Reeves WB, Awad AS. Therapeutic Modalities in Diabetic Nephropathy: Standard and Emerging Approaches. J Gen Intern Med. 2012 Apr;27(4):458-68. PMID: 22005942; PMCID: PMC3304033.
  19. Morris SM, Gao T, Cooper TK, Kepka-Lenhart D, Awad AS. Arginase-2 Mediates Diabetic Renal Injury. Diabetes. 2011 Nov;60(11):3015-22. PMID: 21926276; PMCID: PMC3198072.
  20. Awad AS, Kinsey GR, Khutsishvili K, Gao T, Bolton WK, Okusa MD. Monocyte/Macrophage Chemokine Receptor CCR2 Mediates Diabetic Renal Injury. Am J Physiol Renal Physiol. 2011 Dec;301(6):F1358-66. PMCID: PMC3233863.
  21. Awad AS, Rouse M, Khutsishvili K, Huang L, Bolton WK, Lynch KR, Okusa MD. Chronic Sphingosine 1-Phosphate 1 Receptor Activation Attenuates Early-Stage Diabetic Nephropathy Independent of Lymphocytes. Kidney Int. 2011 May;79(10):1090-8. PMID: 21289599.PMCID: PMC3155206. 
  22. Awad AS, Rouse M, Huang L, Vergis A, Reutershan J, Cathro HP, Linden J, Okusa MD. Compartmentalization of neutrophils in the kidney and lung following acute ischemic kidney injury. Kidney Int. 2009 Apr;75(7):689-98. PMCID: PMC2656389. 
  23. Jo SK, Bajwa A, Ye H, Vergis A, Awad AS, Kharel Y, Lynch KR, Okusa MD. Divergent Roles of Sphingosine Kinases in Kidney Ischemia-Reperfusion Injury. Kidney Int. 2009 Jan;75(2):167-75. PMCID: PMC2646633. 
  24. Jo SK, Bajwa A, Awad AS, Lynch KR, Okusa MD. Sphingosine 1-phosphate Receptors: Biology and Therapeutic Potential in Kidney Disease. Kidney Int. 2008 Jun;73(11):1220-30. PMCID: PMC2614447. 
  25. Awad AS, Michael Rouse, Lixia Liu, Amy L. Vergis, Diane L. Rosin, Joel Linden, John Sedor and Mark D. Okusa. Activation of podocyte adenosine 2A receptors (A2ARs) preserves structural and functional integrity of podocytes. J Am Soc Nephrol. 2008 Jan;19(1):59-68. PMCID: PMC2391028. 
  26. Awad AS, Okusa MD. Distant Organ Injury Following Acute Kidney Injury. Am J Physiol Renal Physiol. 2007 Jul;293(1):F28-9. PMID: 17429033. 
  27. Sharma A, Fernandez L, Awad AS, Kron I, Laubach V. Proinflammatory response of alveolar epithelial cells is enhanced by alveolar macrophage-produced TNF-alpha during pulmonary ischemia-reperfusion injury. Am J Physiol Lung Cell Mol Physiol. 2007 Jul;293(1):L105-13. PMID: 17416740. 
  28. Sevigny CP, Li L, Awad AS, Huang L, McDuffie M, Linden J, Lobo PI, Okusa MD. Activation of Adenosine 2A Receptors Attenuates Allograft Rejection and Alloantigen Recognition. J Immunol. 2007 Apr 1;178(7):4240-9. PMID: 17371980. 
  29. Awad AS, Ye H, Huang L, Foss F, Li L, Macdonald T, Lynch KR, Okusa MD. Selective Sphingosine 1Phosphate 1 (S1P1) Receptor Activation Reduces Ischemia-Reperfusion Injury in Mouse Kidney. . Am J Physiol Renal Physiol. 2006 June;290(6):F1516-24. PMID: 16403835. 
  30. Awad AS, Huang L, Ye H, Duong ET, Bolton WK, Linden J, Okusa MD. Adenosine A2A Receptor Activation Blocks Inflammation and Injury in Diabetic Nephropathy. Am J Physiol Renal Physiol. 2006 Apr;290(4):F828-37. PMID: 16332931. 
  31. Awad AS, Webb RL, Carey RM, Siragy HM. Increased Renal Production of Angiotensin II and Thromboxane B2 in Conscious diabetic Rats. Am J Hypertens. 2005 Apr;18(4 Pt 1):544-8. PMID: 15831366. 
  32. Awad AS, Webb RL, Carey RM, Siragy HM. Renal Nitric Oxide Production is Decreased in Diabetic Rats and Improved by AT1 Receptor Blockade. J Hypertens. 2004 Aug;22(8):1571-7. PMID: 15257181. 
  33. Kalantarinia K, Awad AS, Siragy HM. Urinary and Renal Interstitial Concentrations of TNF-α Increase Prior to the Rise in Albuminuria in Diabetic Rats. Kidney Int. 2003 Oct;64(4):1208-1213. PMID: 12969138. 
  34. Siragy HM, Awad AS, Abadir P, Webb R. The Angiotensin II Type 1 Receptor Mediates Renal Interstitial Content of Tumor Necrosis Factor-alpha in Diabetic Rats. Endocrinology. 2003 Jun;144(6):2229-33. PMID: 12746279. 

BOOK EDITOR

  1. Albuminuria: Symptoms, Causes and Treatment Options. Nova Science Pub Inc; 1 edition (August 31, 2013).

BOOK CHAPTERS

  1. Alhamad T, Abdel-Rahman EM and Awad AS. Albuminuria in Diabetic Nephropathy. In: Albuminuria: Symptoms, Causes and Treatment Options. Nova Science Pub Inc; 1 edition (August 31, 2013).
  2. Roe K, Abdel-Rahman EM, Ghahramani N and Awad AS. Albuminuria in the Elderly. In: Albuminuria: Symptoms, Causes and Treatment Options. Nova Science Pub Inc; 1 edition (August 31, 2013).

INVITED LECTURES AND SYMPOSIUMS

  • 2005 (March): National Kidney Foundation of Virginias. “Reno-Protective Effect of Adenosine 2A Receptor (A2AR) Agonists in Diabetic Nephropathy”.
  • 2005 (October): Northwestern University Feinberg School of Medicine Cardiovascular Young Investigators' Forum. “Adenosine 2A Receptor (A2AR) Agonists Protect Kidneys in a Model of Diabetic Nephropathy”.
  • 2007 (August): University of Texas Health System. “Podocyte Microenvironment in Diabetic Nephropathy”.
  • 2008 (March): University of Washington. “Podocyte Niche in Diabetic Nephropathy: Role of Adenosine 2A Receptors”.
  • 2008 (May): University of Kentucky. “Podocyte Injury in Diabetic Nephropathy: Role of Adenosine 2A Receptors”.
  • 2008 (October): Royal Veterinary College. London, UK. “Podocyte Injury in Diabetic Nephropathy: Role of Adenosine 2A Receptors”.
  • 2009 (January): The Milton S. Hershey Medical Center and the Penn State University College of Medicine. “Macrophages in Diabetic Nephropathy”.
  • 2009 (June): Gordon Research conference Meeting on Nitric Oxide, Lucca (Barga) Italy. “Regulation of Renal Nitric Oxide in Diabetic Nephropathy”.
  • 2009 (September): Northwestern University Feinberg School of Medicine Cardiovascular Young Investigators' Forum. “Blockade of Kidney Macrophage Infiltration Ameliorates Diabetic Nephropathy”.
  • 2012 (May): University of Pittsburgh, Department of Medicine. “Arginase-2: An Emerging Key Player in Diabetic Kidney Disease”.
  • 2012 (August): Drexel University, Department of Physiology & Pharmacology. “Role of Arginase in Diabetic Nephropathy”.
  • 2012 (September): University of Mississippi, Department of Physiology. “Arginase/Nitric Oxide Interaction in Diabetic Nephropathy”.
  • 2016 (January): University of Pittsburgh, Renal Grand Round. “Arginase/Nitric Oxide Interaction in Diabetic Nephropathy”.
  • 2016 (January): Baylor College of Medicine, Children’s Nutrition Research Center. “Arginase/Nitric Oxide Interaction in Diabetic Nephropathy”.
  • 2016 (January): Baylor College of Medicine, Renal Grand Round. “Arginase-2: An Emerging Key Player in Diabetic Kidney Disease”.
  • 2016 (September): Harvard Institute of Medicine, Renal Conference. “Arginase-2: An Emerging Key Player in Diabetic Kidney Disease”.
  • 2016 (October): University of Texas Health System, Renal Grand Round. “Arginase-2: An Emerging Key Player in Diabetic Kidney Disease”.
  • 2017 (February): LS2 Annual Meeting 2017, Zürich. “Arginase-2: An Emerging Key Player in Diabetic Kidney Disease”.
  • 2019 (September): Stony Brook University, Renal Grand Round. “Arginase/Nitric Oxide Interaction in Diabetic Nephropathy”.
  • 2020 (March): University of Maryland, Renal Grand Round. “Arginase/Nitric Oxide Interaction in Diabetic Nephropathy”.